Loading CASI total return...
Loading summary...

About CASI Dividend Returns

CASI Pharmaceuticals, Inc. (CASI) is a dividend-paying stock. When dividends are reinvested through a DRIP (Dividend Reinvestment Plan), they purchase additional shares, which then generate their own dividends—creating a compounding effect that can significantly boost long-term returns.

How We Calculate Total Return

Our total return calculator simulates dividend reinvestment (DRIP) by assuming each dividend payment is used to purchase additional shares at the closing price on the ex-dividend date. This methodology provides an accurate representation of how a dividend reinvestment plan would perform.

Frequently Asked Questions

Q1What is the total return of CASI over the past year?

CASI Pharmaceuticals, Inc. (CASI) delivered a total return of -90.78% over the past year when dividends are reinvested. The price-only return was -90.78%, meaning dividends contributed an additional 0.00 percentage points to total returns.

Q2How much would $10,000 invested in CASI be worth today?

A $10,000 investment in CASI Pharmaceuticals, Inc. one year ago would be worth $922 today with dividends reinvested (DRIP). Without reinvesting dividends, the same investment would be worth $922. Dividend reinvestment added $0 to the portfolio value.

Q3Does CASI pay dividends?

Yes, CASI Pharmaceuticals, Inc. (CASI) pays dividends. In the last year, CASI paid approximately $0.05 per share in dividends (22.56% yield). Reinvesting these dividends through a DRIP can significantly boost long-term returns — over 20+ years, dividend compounding can account for 30–50% of total returns for dividend-paying stocks.

Q4Did CASI beat the S&P 500?

No, CASI Pharmaceuticals, Inc. (CASI) underperformed the S&P 500 by 106.23 percentage points over the past year. CASI delivered a total return of -90.78%, compared to the S&P 500's 15.45%. This means a passive S&P 500 index fund outperformed CASI by 106.23pp during this period.

Q5What is CASI's worst drawdown?

CASI Pharmaceuticals, Inc. (CASI) experienced a maximum drawdown of -91.60% over the past year, declining from its peak on 2025-08-21 to its trough on 2026-02-25. The stock has not yet fully recovered to its prior peak. Maximum drawdown measures the worst peak-to-trough decline and is an important risk metric for investors.

Q6What is CASI's long-term total return over 10, 20, or 30 years?

CASI Pharmaceuticals, Inc. (CASI) has delivered strong long-term returns with dividends reinvested. Over 10 years, the total return is -97.4% (-30.5% CAGR) — $10,000 would have grown to $263. Over 20 years: -99.9% total return (-30.1% CAGR) — $10,000 → $8. Over 30 years: -100.0% total return (-26.0% CAGR) — $10,000 → $1. Long-term investors benefit from compounding: dividends buy additional shares, which generate their own dividends, creating an exponential growth effect.

Q7What was CASI's best and worst year?

CASI Pharmaceuticals, Inc.'s best calendar year was 2009 with a total return of 400.0%. Its worst year was 2002 with a total return of -89.6%. This range shows the volatility investors should expect — the difference between the best and worst year is 489.6 percentage points.

💰

Find the Best Dividend Stocks

Screen for dividend stocks with the highest total returns (including DRIP).

View Dividend Stocks →

Compare Similar Stocks

Deep Dive into CASI